XM does not provide services to residents of the United States of America.
S
S

Stryker

News

Medical device maker Baxter beats sales and profit estimates on strong demand

Medical device maker Baxter beats sales and profit estimates on strong demand Feb 8 (Reuters) - Baxter International BAX.N beat Wall Street expectations for fourth-quarter sales and profit on Thursday on strong demand for its medical devices and improvements in the supply chain environment. Expectations around performance of medical device makers have increased over the past month after health insurers flagged higher medical costs as people, especially older adults, undergo medical procedures th
S

S&P 500 top and bottom performing stocks at about 03:30 p.m. EST

BUZZ - S&P 500 top and bottom performing stocks at about 03:30 p.m. EST S&P 500 .SPX Top Performers Percent Change Paramount Global PARA.OQ +7.4% Stryker Corp SYK.N +7.1% Edwards Lifesciences Corp EW.N +6.3% Boeing Co BA.N +5.4% Fortive Corp FTV.N +5.1% Bottom Performers Percent Change Marketaxess Holdings Inc MKTX.OQ -17.4% Rockwell Automation Inc
B
G
T
U
S
F
M

U.S. STOCKS Boeing, Mondelez International, Novavax

BUZZ-U.S. STOCKS ON THE MOVE-Boeing, Mondelez International, Novavax Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 The tech-heavy Nasdaq tumbled to more than a week low on Wednesday, as Alphabet's projections for rising AI costs dented most megacap and chip stocks ahead of a crucial U.S.
A
B
G
M
M
M
M
M
N
Q
S
T
T
A
A
U
U
S
T

Stryker hits record high on upbeat 2024 forecast, brokerages raise PT

BUZZ-Stryker hits record high on upbeat 2024 forecast, brokerages raise PT ** Shares of medical device maker Stryker Corp SYK.N rise 6.6% to $337.59, a record high ** Co on Tuesday forecast 2024 profit above Wall Street estimates, upbeat Q4 results ** Sees 2024 adj EPS to be $11.70-$12.00 vs analysts' estimates of $11.56 - LSEG ** At least 10 brokerages raise PT on co ** Deutsche Bank raises PT to $345 from $300; Jefferies raises PT to $390 from $345 ** Big Q4 beat sets the stage for a strong 20
S

Stryker Corp reports results for the quarter ended in December - Earnings Summary

Stryker Corp reports results for the quarter ended in December - Earnings Summary Stryker Corp SYK.N reported quarterly adjusted earnings of $3.46​​ per share for the quarter ended in December, higher than the same quarter last year, when the company reported EPS of $3.00. The mean expectation of twenty six analysts for the quarter was for earnings of $3.27 per share.
S

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.